%0 Journal Article
%A Nyssen, Olga P
%A Vaira, Dino
%A Saracino, Ilaria Maria
%A Fiorini, Giulia
%A Caldas, María
%A Bujanda, Luis
%A Pellicano, Rinaldo
%A Keco-Huerga, Alma
%A Pabon-Carrasco, Manuel
%A Oblitas Susanibar, Elida
%A Di Leo, Alfredo
%A Losurdo, Giuseppe
%A Pérez-Aísa, Ángeles
%A Gasbarrini, Antonio
%A Boltin, Doron
%A Smith, Sinead
%A Phull, Perminder
%A Rokkas, Theodore
%A Lamarque, Dominique
%A Cano-Català, Anna
%A Puig, Ignasi
%A Mégraud, Francis
%A O'Morain, Colm
%A Gisbert, Javier P
%T Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg).
%D 2022
%@ 2077-0383
%U http://hdl.handle.net/10668/21257
%X First-line Helicobacter pylori (H. pylori) treatments have been relatively well evaluated; however, it remains necessary to identify the most effective rescue treatments. Our aim was to assess the effectiveness and safety of H. pylori regimens containing rifabutin. International multicentre prospective non-interventional European Registry on H. pylori Management (Hp-EuReg). Patients treated with rifabutin were registered in AEG-REDCap e-CRF from 2013 to 2021. Modified intention-to-treat and per-protocol analyses were performed. Data were subject to quality control. Overall, 500 patients included in the Hp-EuReg were treated with rifabutin (mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump-inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance with treatment was 89%. At least one adverse event was registered in 26% of the patients (most frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukopenia and thrombocytopenia with fever requiring hospitalisation. Rifabutin-containing therapy represents an effective and safe strategy after one or even several failures of H. pylori eradication treatment.
%K H. pylori
%K Helicobacter pylori
%K Hp-EuReg
%K bismuth
%K culture
%K eradication failure
%K rescue
%K rifabutin
%K treatment
%~